Please turn JavaScript on
Homepage
TrendingMy newsFind FeedsDelivery settingsPlansMy earnings
HelpBlog
Log in
Find more feeds

Stevenage Bioscience Catalyst

Want to know the latest news and articles posted on Stevenage Bioscience Catalyst?

Then subscribe to their feed now! You can receive their updates by email, via mobile or on your personal news page on this website.

See what they recently published below.

Website title: Stevenage Bioscience Catalyst: Empowering Innovation

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.14 / day

Message History

Stevenage Bioscience Catalyst Featured in BBC Coverage of Oxford Cambridge Growth Corridor
Stevenage Bioscience Catalyst Featured in BBC Coverage of Oxford Cambridge Growth Corridor Stevenage Bioscience Catalyst has been featured on BBC News as part of coverage examining the Oxford Cambridge Growth Corridor and its potential economic impact.

The article reports that the corridor could contribute up to £78bn to the UK economy by 2035, driven by knowledge intensive i...


Read full story
Welcome Afortiori Bio to Stevenage Bioscience Catalyst
Read full story
SBC is hiring a Commercial Asset Manager (Part Time)
Read full story
Complement Therapeutics Receives UK CTA Approval to Advance CTx001 into Opti-GAIN Phase I/II Clinical Trial in Geogr...
Complement Therapeutics Receives UK CTA Approval to Advance CTx001 into Opti-GAIN Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD · CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways within the complement system · UK Clinical Trial Authorisation (CTA) approval enables initiation of the Phase I/II Opti-GAIN cl...

Read full story
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is...
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s Stevenage, UK, 8 January 2026 – NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction...

Read full story